Edition:
United States

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

44.02USD
14 Dec 2017
Change (% chg)

$-1.17 (-2.59%)
Prev Close
$45.19
Open
$45.30
Day's High
$45.79
Day's Low
$43.86
Volume
115,525
Avg. Vol
161,893
52-wk High
$91.17
52-wk Low
$43.44

Chart for

About

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $1,874.77
Shares Outstanding(Mil.): 42.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN

Dec 15 2017

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

Dec 04 2017

BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301

* Ultragenyx announces completion of patient dosing in first cohort of phase 1/2 clinical study of dtx301 gene therapy in ornithine transcarbamylase (OTC) deficiency

Nov 16 2017

BRIEF-ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

* ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

Nov 15 2017

FDA approves Ultragenyx drug for rare enzyme disorder

The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.

Nov 15 2017

UPDATE 1-U.S. FDA approves Ultragenyx drug for rare enzyme disorder

Nov 15 The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.

Nov 15 2017

BRIEF-FDA approves Ultragenyx Pharmaceutical's Mepsevii for rare genetic enzyme disorder‍​

* Approved Ultragenyx Pharma's Mepsevii to treat pediatric, adult patients with inherited metabolic condition called mucopolysaccharidosis TYPE VII ‍​ Further company coverage:

Nov 15 2017

BRIEF-Ultragenyx reports third quarter 2017 financial results

* Ultragenyx Pharmaceutical Inc- ‍cash, cash equivalents, and investments were $396.0 million as of September 30, 2017​

Nov 02 2017

BRIEF-Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

* Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

Nov 01 2017

BRIEF-ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

* ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

Oct 10 2017

Earnings vs. Estimates